ONCY ONCOLYTICS BIOTECH INC
Company Analysis
Latest News
Oncolytics Reports 15-Month Median Response Duration in Pelareorep Anal Cancer Study
Oncolytics Biotech Inc. announced positive updated clinical data from its Phase 1/2 GOBLET study for its investigational immunotherapy, pelareorep. The results...
🔴 Oncolytics Biotech is trading 5.51% down today with no verified catalyst identified
Oncolytics Biotech is trading 5.51% lower at $0.47, with no verified catalyst identified for the decline. - Major U.S. indexes were higher, so the decline did...
🟢 Oncolytics Biotech is trading 5% up today amid likely biotech-sector strength
Oncolytics Biotech is trading at $0.52, up 5.10%, with biotech-sector strength the likelier context; no clear company-specific catalyst was identified. - The...
🔴 Oncolytics Biotech is trading 10% down
Oncolytics Biotech is trading 10.03% lower at $0.49, with no verified company-specific announcement or reliable report directly explaining the October 16...
🔴 Oncolytics Biotech is trading 6.3% down with no confirmed catalyst
Oncolytics Biotech is trading 6.32% down at $0.51, with no verified explanation identified for the October 16 decline. - No verified company-specific...
🟢 Oncolytics Biotech is trading 7.74% up in after-hours trading
Oncolytics Biotech is trading at $0.59, up +7.74%, with no verified October 15 after-hours announcement or specific catalyst identified. - The broader market...
🟢 Oncolytics Biotech is trading 5% up after GOBLET enrollment update
Oncolytics Biotech is trading 5.02% up at $0.57 on October 15, 2026, following its GOBLET enrollment update; available reporting does not explicitly attribute...
🟢 Oncolytics Biotech is trading 11% up with GOBLET enrollment complete
Oncolytics Biotech is trading 11% up at $0.54, with its October 14, 2026 announcement offering possible company-specific context; it did not attribute the gain...
🟢 Oncolytics Biotech is trading 6% up today
Oncolytics Biotech is trading 5.98% higher at $0.52, with no clear reason established for the intraday gain. - On October 14, the company updated its GOBLET...
🔴 Oncolytics Biotech is trading 7.4% down — no clear company-specific catalyst
Oncolytics Biotech is trading at $0.45, down 7.37%, with no clear company-specific news explaining the decline. - Price was reported at 9:47 a.m. Eastern on...
🟢 Oncolytics Biotech is trading 5% up today after announcement of pelareorep method-of-use patents
Oncolytics Biotech is trading at $0.50, up +5.32%, following its announcement of new pelareorep method-of-use patents; coverage has not confirmed the...
Oncolytics Secures New Patents for Pelareorep, Extending Protection into the Late 2040s
Oncolytics Biotech Inc. announced a strategic update on its intellectual property portfolio for its lead immunotherapy candidate, pelareorep. The company has...
🟢 Oncolytics Biotech is trading 5.64% up in pre-market — patent update is a possible catalyst
Oncolytics Biotech is trading at $0.50, up 5.64% in pre-market, with its patent announcement a plausible but unconfirmed overnight catalyst. - On October 12,...
🟢 Oncolytics Biotech is trading 5.66% up in after-hours trading — cause unconfirmed
Oncolytics Biotech is trading at $0.50, up 5.66%, in after-hours trading; the cause of the rise remains unconfirmed. - No confirmed company-specific...
🔴 Oncolytics Biotech is trading 10.2% down — catalyst remains unconfirmed
Oncolytics Biotech is trading 10.22% down at $0.50, with the cause of the October 12, 2026 decline unconfirmed. - The company reported accelerating enrollment...
🔴 Oncolytics Biotech is trading 6% down — cause remains unconfirmed
Oncolytics Biotech is trading at $0.53, down -5.55%, with the decline unexplained. - No reliable report ties the October 12 decline to a specific company...
🟢 Oncolytics Biotech is trading 5% up in pre-market with no confirmed catalyst
Oncolytics Biotech is trading 5.31% higher at $0.59 in pre-market on October 12, versus its October 9 close of $0.56. No reliable source directly attributes...
🔴 Oncolytics Biotech is trading 5% down amid biotech-sector weakness
Oncolytics Biotech is trading at $0.57, down 5.14%, amid biotech-sector weakness; no clear catalyst for the decline was identified. - An October 8 search...
🟢 Oncolytics Biotech is trading 5.6% up in pre-market
Oncolytics Biotech is trading 5.55% up at $0.63 in the supplied pre-market price context, with no clear company-specific catalyst identified. - The stock...
🟢 Oncolytics Biotech is trading 5.6% up in after-hours trading with no confirmed catalyst
Oncolytics Biotech is trading at $0.63, up 5.55% in after-hours trading; the catalyst remains unclear. - It closed the regular session at $0.60 on October 5,...